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Abstract
Pre-existing immunity to human adenovirus serotype 5 (Ad5) is common in the general population. Bypassing pre-existing
immunity could maximize Ad5 vaccine efficacy. Vaccination by the intramuscular (I.M.), nasal (I.N.) or oral (P.O.) route with
Ad5 expressing Ebola Zaire glycoprotein (Ad5-ZGP) fully protected naı ¨ve mice against lethal challenge with Ebola. In the
presence of pre-existing immunity, only mice vaccinated I.N. survived. The frequency of IFN-c+ CD8+ T cells was reduced by
80% and by 15% in animals vaccinated by the I.M. and P.O. routes respectively. Neutralizing antibodies could not be
detected in serum from either treatment group. Pre-existing immunity did not compromise the frequency of IFN-c+ CD8+ T
cells (3.961% naı ¨ve vs. 3.661% pre-existing immunity, PEI) nor anti-Ebola neutralizing antibody (NAB, 40610 reciprocal
dilution, both groups). The number of INF-c+ CD8+ cells detected in bronchioalveolar lavage fluid (BAL) after I.N.
immunization was not compromised by pre-existing immunity to Ad5 (146614, naı ¨ve vs. 120616 SFC/million MNCs, PEI).
However, pre-existing immunity reduced NAB levels in BAL by ,25% in this group. To improve the immune response after
oral vaccination, the Ad5-based vaccine was PEGylated. Mice given the modified vaccine did not survive challenge and had
reduced levels of IFN-c+ CD8+ T cells 10 days after administration (0.360.3% PEG vs. 1.760.5% unmodified). PEGylation did
increase NAB levels 2-fold. These results provide some insight about the degree of T and B cell mediated immunity
necessary for protection against Ebola virus and suggest that modification of the virus capsid can influence the type of
immune response elicited by an Ad5-based vaccine.
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Introduction
The ability of human adenoviruses to induce strong innate and
adaptive immune responses makes them powerful adjuvants that
facilitate the immune response against an encoded antigen.
Recombinant adenoviruses have been shown to elicit significant
immune responses to bacterial (anthrax, plague), viral (Hepatitis C,
Rabies, SARS) and tumour-associated antigens [1–3]. While these
results are encouraging, immunity eventually develops against
virus capsid proteins. This severely reduces the immunogenicity of
adenovirus-based vaccines in mice, [4–8], primates [9] and
humans [10]. This problem is also significant since a large portion
of the Western world has marked levels of anti-adenovirus serotype
5 (Ad5) antibodies and is also prominent in regions of sub-Saharan
Africa and Southeast Asia, where many of these vaccines are
needed [11,12]. Thus, assessment of the impact of pre-existing
immunity on immune protection and alternative vaccination
strategies may be needed for successful use of many adenovirus-
based vaccines.
Several strategies have been developed to address the
prevalence of pre-existing immunity to Ad5 in the general
population. Increasing the vector dose or adopting a prime-boost
regimen in order to overcome pre-existing immunity to the virus is
a common approach [2]. There is mixed enthusiasm for this plan,
however, due to the documented toxicity associated with high
doses of adenovirus and the length of time required for prime-
boost regimens when only a prime could be sufficient [13,14].
‘Seroswitching’, using recombinant adenoviruses constructed from
chimpanzees or rare human serotypes with limited exposure rates
such as adenoviruses 35 and 11 can elicit potent immune responses
that are minimally affected by pre-existing immunity [7,8,15–21].
Hexon-chimeric adenoviruses can also avoid neutralization
[22,23]. Both approaches offer promise in the context of
addressing pre-existing immunity, but require further investigation
in response to concerns regarding safety and feasibility of large-
scale production. Covalent attachment of polyethylene glycol or
incorporation of the virus into polymer matricies can also
effectively protect Ad5 from neutralization [24–31]. Delivery of
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effect of pre-existing immunity and induce a significant immune
response against an encoded antigen [32].
Recombinant adenoviruses are one of the few well-studied
vectors currently under development for vaccination against Ebola
virus infection. The first protocol for an Ebola vaccine employed a
prime-boost regimen consisting of naked DNA expressing either
Ebola glycoprotein (GP) or nucleoprotein (NP) and recombinant
Ad5 expressing Ebola GP to successfully protect non-human
primates against a lethal challenge of Ebola [33]. This has since
led to several Phase I clinical trials [34,35] in which each
component of the vaccine is administered by intramuscular
injection. To date, there have been only two reports describing
mucosal administration of an Ebola vaccine [36,37]. Nasal
administration of recombinant human parainfluenza virus type 3
(HPIV3) vectors expressing Ebola GP and/or NP to Guinea pigs
and rhesus monkeys conferred complete protection against a lethal
challenge with Ebola.
We have previously found that a single dose of a recombinant
adenovirus expressing Ebola Zaire GP given by either the oral or the
nasal route is capable of affording protection against lethal challenge
in naı ¨ve miceand that mucosal immunization can stimulate a broad,
prolonged T cell-mediated immune response in both the systemic
and mucosal compartments [37].The primaryobjective ofthisstudy
was to test the hypothesis that administration of an Ad5-based Ebola
vaccine by either the nasal or oral route can circumvent pre-existing
immunity and confer full protection upon challenge. Systemic and
mucosal T and B cell responses to Ebola GP were assessed in both
naı ¨ve mice and those with pre-existing immunity. The influence of
PEGylation of the vaccine carrier on the immune response after oral
immunization is also described.
Materials and Methods
Construction, production and formulation of adenoviral
vectors
The E1/E3-deleted adenovirus vector expressing the Ebola Zaire
glycoprotein was created by cloning the open reading frame (ORF)
sequence of the glycoprotein in the plasmid pShuttle (Adeno-X
Expression system I, BD Clonetech, Palo Alto, CA) for subsequent
insertion in the E1 region of the human adenovirus serotype 5
genome. The human cytomegalovirus (CMV) promoter included in
the Adeno-X expression system was used to drive the expression of
the Ebola Zaire glycoprotein in the final recombinant adenovirus
serotype 5 construct. Authenticity of the final productwas confirmed
by sequencing of the recombinant virus rescued by transfecting the
linearized DNA into 293 cells. Virus was sequentially amplified to
large-scaleinfections(5610
8 cells)andpurifiedonanaffinitycolumn
(Adeno-X virus purification mega kit, BD Clonetech, Mountain
View, CA) according to the manufacturer’s instructions. Genome
structuresof vectorswereanalyzed byrestriction digestion ofisolated
viralDNAandcomparedwiththoseoftheoriginalmolecularclones.
Particle number and infectivity of vectors were determined by
standard optical density reading and immunodetection of the hexon
protein, respectively, following infection of 293 cells with limiting
dilutions of each vector preparation according to the recommenda-
tions by the manufacturer (Adeno-X rapid titer kit, Clontech,
Mountain View, CA). Purified virus was administered in sterile
phosphate buffered saline (pH 7.4) and had particle to plaque
forming unit (pfu) ratios of 100:1 or less.
PEGylation of recombinant adenovirus
First generation recombinant adenovirus expressing Ebola Zaire
glycoprotein was prepared and purified as described above. The
protein content of the virus preparation was determined using
BioRad DC Protein Assay reagents (BioRad, Hercules, CA) and
bovine serum albumin as a standard in a microplate format.
According to established protocols, 10 mg of monomethoxypo-
ly(ethylene) glycol, activated by tresyl chloride (Sigma Aldrich, St.
Louis, MO), was added for each microgram of protein present
[38]. The coupling reaction was performed at 25uC with gentle
agitation. The reaction was stopped by the addition of L-lysine, in
a 10-fold excess with respect to the amount of PEG added.
Unreacted PEG, excess L-lysine, and reaction byproducts were
removed by buffer exchange over a second Econo-Pac 10DG
disposable chromatography column equilibrated with 100 mM
potassium phosphate-buffered saline (pH 7.4). PEGylated prepa-
rations were administered in sterile potassium phosphate buffered
saline (pH 7.4) and had particle to plaque forming unit (pfu) ratios
of 100:1 or less as determined by the Adeno-X rapid titer kit.
Characterization of these preparations revealed significant chang-
es in biophysical properties of the virus once the reaction was
complete such as the PEG-Dextran partition coefficient and peak
elution times during capillary electrophoresis (as described
previously [30,38]). Approximately 13,000 PEG molecules were
associated with each virus particle in the studies outlined here as
determined by a PEG-biotin assay [30].
Immunization of mice and challenge
B10.BR mice were immunized with 1610
10 particles of
recombinant virus per mouse either by intramuscular injection
(50 ml) in the right hindlimb, or by oral gavage (100 ml) using oral
feeding needles (18G, 2.25 mm dia., Popper & Sons, Inc, New
Hyde Park, NY). For nasal immunization, mice were anesthetized
with isoflurane. Once anesthesia was achieved, 1610
10 particles of
virus slowly delivered as a bolus into the nostrils using a standard
micropipette (Gilson, Middleton, WI) as previously described [39].
Pre-existing immunity to adenovirus serotype 5 was established
by injecting 5610
10 particles of adenovirus expressing beta-
galactosidase (AdlacZ) by intramuscular injection in the right
hindlimb 30 days prior to vaccination with Ad5-ZGP. This
protocol has been documented to activate T and B cells against
virus capsid proteins and elicit humoral immunity [8,11]. At the
time of vaccination, mice had an average anti-adenovirus
circulating NAB titer of 1:320, which falls within lower range of
average values reported in humans after natural infection [11].
Mice were challenged by intraperitoneal injection of 2006LD50 of
mouse-adapted Ebola virus, Zaire strain (MA-ZEBOV) in 200 ml
sterile saline [40]. After challenge, the animals were weighed daily
for 13 days and monitored for clinical signs of Ebola infection
using an approved scoring sheet. All procedures and the scoring
method were approved by the Institutional Animal Care
Committee at the National Microbiology Laboratory (NML) of
the Public Health Agency of Canada (PHAC) according to the
guidelines of the Canadian Council on Animal Care. All infectious
work was performed in the ‘Biosafety Level 4’ (BSL4) facility at
NML, PHAC.
Antibody detection assays
A) Anti-ebola neutralizing antibody (serum). Sera
collected from immunized mice were inactivated at 56uC for
45 minutes. Serial dilutions of each sample (1:10, 1:20, 1:40, etc,
in 50 ml of DMEM) were mixed with equal volumes of
recombinant Ebola Zaire expressing the enhanced green
fluorescent protein (EGFP) reporter gene (ZEBOV-EGFP, 100
transducing units/well, according to EGFP expression) and
incubated at 37uC for 90 minutes [41]. The mixture was then
added to subconfluent VeroE6 cells in 96-well flat-bottomed plates
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wells were infected with equal amounts of either ZEBO-EGFP
with media without serum or that containing non-immune serum.
100 ml of DMEM supplemented with 20% FBS was then added to
each well and plates were incubated at 37uCi n5 %C O 2 for 48 hr.
Cells were subsequently fixed with 10% buffered formalin for 24 h
and examined under a fluorescent microscope. Sample dilutions
which showed .50% reduction in the number of green cells
compared to controls scored positive for neutralizing antibody.
B) Anti-ebola neutralizing antibody (mucosal). For the
evaluation of the specific levels of IgG and IgA antibodies,
bronchoalveolar lavage (BAL) fluid was collected in situ with a 20-
gauge catheter inserted into the proximal trachea, flushing the
lower airways three times with 1 milliliter of L15 media (Sigma).
BAL from each animal was incubated at 56uC for 45 minutes.
Two-fold serial dilutions were added to 96 well plates pre-coated
overnight with 30 ng of ZEBOV-like particles per well and
incubated at 37uC for 1 hr. Goat anti-mouse secondary antibody
conjugated to horseradish peroxidase (HRP) was then added and
the plate was incubated for one additional hour at 37uC. The
ABTS Peroxidase Substrate System (KPL) was used for detection
and data collected using an ASYS UVM 340 ELISA plate reader
(Isogen Life Science) at OD405. All infectious in vitro work was
performed in the BSL4 laboratory at the NML, PHAC.
C) Anti-adenovirus serotype 5 neutralizing antibody
(serum). Pre-existing immunity against recombinant adenovirus
5 was assessed by determining the amount of neutralizing antibody
present in serum according to established methods [30]. In brief,
serum was incubated at 56uC for 30 minutes and then diluted in
DMEM in twofold increments starting from a 1:20 dilution. Each
dilution (100 ml) was mixed with an aliquot of a standard stock of
adenovirus type 5 expressing E. coli beta-galactosidase (10
6 pfu),
incubated for 1 hour at 37uC, and applied to HeLa cells in 96-well
plates (2610
4 cells/well). One hundred microliters of DMEM
supplemented with 20% FBS was then added to each well. Cells
were incubated at 37uC for 24 hours. Neutralizing antibody titers
were calculated as the highest dilution at which 50% of the cells
stained blue by visual inspection.
Frequency of INF-c positive cells
For the evaluation of INF-c positive CD8+ T cells 10 days post-
immunization, splenocytes were harvested and cultured (1610
6/
sample) for 5 hours at 37uC in 96-well round bottom microtiter
plates in DMEM supplemented with 10% FBS, 2-beta-mercapto-
ethanol (10
26 M) and GolgiStop (1 ml/ml, BD PharMingen, San
Diego, CA). The TELRTFSI peptide which carries the Ebola Zaire
GP immunodominant MHC class I epitope for mice of the H-2
k
haplotype (B10.BR) was used for stimulation at a concentration of
1 mg/ml [42]. Control cells were treated with either an unrelated
peptide or no peptide. After washing, cells were stained with 100 ml
of a FITC-anti mouse CD8a antibody (1:100 dilution, PharMingen)
at 4uC for 30 minutes. Cells were washed again, permeabilized in
16Cytofix/Cytoperm (PharMingen) for 20 minutes at 4uC, washed
with 16Perm/Wash (PharMingen) and stained with 100 ml of a PE-
antimouseIFN-cantibody(1:100dilution,PharMingen)inthesame
buffer at 4uC for 30 minutes.
Quantitation of INF-c positive CD8+ T cells isolated from
splenocytes or mononuclear cells from bronchioalveolar lavage
(BAL), mesenteric lymph nodes (MLN) and Peyer’s patches (PP) 45
days after vaccination was performed using an ELISPOT assay
(ELISPOT Mouse Set, BD PharMingen, San Diego, CA)
according to the manufacturer’s instructions. Briefly, a 96-well
ELISPOT plate was coated with 5 mg/ml anti-mouse IFN-c
capture antibody. Cells pooled from 4 B10.BR mice per
experimental group were added to microwells along with the
TELRTFSI peptide (2 mg/well). Control cells were incubated
either without peptide or with the non-specific stimulator, SEB
(200 ng/ml). After incubation with a biotinylated anti-mouse IFN-
c detection antibody and Streptavidin-horseradish peroxidase
antibody, wells were counted using an ELISPOT reader (AID
EliSpot reader system, Cell Technology, Colombia, MD).
Statistical analysis
Data were analyzed for statistical significance by performing
unpaired T tests (two-tailed p value) or one-way analysis of
variance (ANOVA) when appropriate. The differences in the
mean or raw values among treatment groups were considered
significant when p,0.05.
Results
Effect of Mucosal Immunization on T and B Cell
Responses Against Ebola Glycoprotein in Mice with Pre-
Existing Immunity Against Adenovirus
In an effort to correlate markers of immunity with protection
against Ebola infection after mucosal immunization, T and B cell
specific immune responses against Ebola glycoprotein were analyzed
in mice in the presence or absence of pre-existing immunity (PEI) to
adenovirus 10 days after vaccination with a first generation
adenovirusserotype5vectorexpressingtheZaireEbolaglycoprotein
(Ad5-ZGP). Intracellular staining and flow cytometry (FACS)
revealed that Ebola glycoprotein peptide-specific activation of
CD8+ T cells, as measured by production of IFN-c,o c c u r r e di n
naı ¨ve animals immunized by the nasal route at a frequency of
3.961% (I.N., Figure 1A). Pre-existing immunity was induced by
intramuscular administration of recombinant Ad5 expressing a non-
relevant antigen, beta-galactosidase (AdlacZ), 30 days prior to
vaccination with Ad5-ZGP. At the time of vaccination, mice had an
average anti-adenovirus circulating NAB titer of 1:320. Pre-existing
immunity did not significantly alter activation of CD8+ T cells when
the vaccine was given intranasally (I.N.+PEI, 3.661%, p=0.07).
Oral immunization lowered the response against Ebola glycoprotein
(P.O., 260.5%). Samples obtained from animals with pre-existing
immunity and vaccinated in the same manner were barely above the
positive threshold (three times the average background level
obtained from animals treated with the irrelevant virus, AdlacZ).
Samples obtained from naı ¨ve animals immunized by the intramus-
cular route (I.M.) contained the largest population of IFN-c positive
CD8+ T cells (1062%). Animals treated with the AdlacZ vector
alone (AdlacZ-control) served as negative controls and produced
0.5% CD8+,I F N - c+ T cells in response to the Ebola glycoprotein-
specific peptide.
The B cell response against Ebola glycoprotein achieved by
administration of the vaccine was determined by incubating a
recombinant Ebola virus (Zaire strain) expressing green fluorescent
protein (ZEBOV-EGFP) with serum collected 25 days after
vaccination [8,37]. Neutralizing antibody (NAB) levels equivalent
to 40610 reciprocal dilution were detected in both naı ¨ve animals
and those with pre-existing immunity after intranasal immuniza-
tion (Figure 1B). Samples from naı ¨ve animals immunized by the
oral route contained NAB levels equivalent to 2065 reciprocal
dilution whereas anti-Ebola NAB could not be detected in samples
obtained from animals immunized by the same route with pre-
existing immunity (P.O.+PEI). NAB levels of 80610 were detected
in samples obtained from naı ¨ve mice immunized by the
intramuscular route. Anti-Ebola NAB could not be detected in
samples from mice given the AdlacZ vector alone (AdlacZ
Control).
Nasal Immunization for Ebola
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Localized T-Cell Mediated Immune Responses Against
Ebola Glycoprotein in Mice with Pre-Existing Immunity
Since the mucosa is often the primary sight of exposure, long-
term, localized immune responses against Ebola virus are desirable
for providing optimal protection against infection. In this context,
T cell mediated immune responses were assessed by ELISPOT
from various tissue compartments specific to the route of
immunization 45 days after vaccination. The number of activated
IFN-c secreting mononuclear cells harvested from splenocytes was
significantly reduced by 38 and 59% in mice vaccinated nasally or
orally when compared to those immunized by intramuscular
injection (p#0.05, Figure 2A). In contrast, samples obtained from
the spleen of animals with pre-existing immunity that were
immunized by the I.N. route contained the highest number of
activated IFN-c secreting cells (8156190 spot-forming cells (SFC)/
million mononuclear cells (MNCs), Figure 2C) although this was
approximately 30% lower than that seen in naive animals
(1,3406146 SFC/million MNCs, Figure 2A). Pre-existing immu-
nity also significantly reduced the number of these cells produced
by animals immunized by the I.M. (210668 SFC/million MNCs)
and P.O. routes (71612 SFC/million MNCs) with respect to those
seen in naı ¨ve animals (2,145612 (I.M.) and 8856168 (P.O.)),
p#0.05, Figure 2A). A very limited number of activated IFN-c
secreting mononuclear cells were detected in splenocytes of naı ¨ve
animals immunized with the AdlacZ vector (50620 SFC/million
MNCs, Figure 2A) and those with pre-existing immunity to the
same virus (1261, AdlacZ, Figure 2C). Significant levels of INF-c
positive cells were detected in bronchioalveolar lavage fluid (BAL)
after intranasal immunization (146614 SFC/million MNCs,
p#0.05, Figure 2B). This was not significantly compromised by
pre-existing immunity to adenovirus (120616 SFC/million
MNCs, p#0.06, Figure 2D). A limited number of INF-c secreting
cells were detected in BAL from naı ¨ve animals immunized by the
I.M. or P.O. routes (462 and 1165 SFC/million MNCs
respectively, Figure 2B) and were similar to that seen in samples
obtained from animals given the AdlacZ vector (1261, negative
control). Pre-existing immunity to adenovirus reduced these cell
populations further to values that were not statistically significant
(161 (I.M.), 562 (P.O.) and 261 (AdlacZ) SFC/million MNCs
(p=0.08, Figure 2D)). INF-c positive cells were found in
mesenteric lymph nodes (MLN) and Peyer’s Patches (PP)
(146611 and 2965 SFC/million MNCs, respectively) only after
oral vaccination with Ad-ZGP (Figure 2B). Pre-existing immunity,
however, reduced production of these cells to 18612 SFC/million
MNCs (MLN) and 1662 SFC/million MNCs (PP) (Figure 2D).
Effect of Mucosal Immunization on Localized and
Systemic Antibody Production Against Ebola
Glycoprotein
The NAB response was also monitored from bronchioalveolar
lavage fluid 45 days post-vaccination. NAB to ZEBOV-EGFP was
undetectable in samples obtained from control (AdlacZ) or I.M.
immunized mice, whereas levels of 40610 and 1065 reciprocal
dilution were detected in the BAL of nasally and orally vaccinated
animals, respectively (Figure 3). Those with pre-existing immunity
and immunized by the nasal route had NAB levels of 30610. NAB
was not detected in mice with pre-existing immunity to Ad5 and
immunized by either the intramuscular or oral route.
Further characterization of Ebola glycoprotein-specific immu-
noglobulin isotypes obtained from bronchioalveolar lavage fluid
revealed that pre-existing immunity correlated with a marked
decrease in the production of both IgG and IgA antibodies in mice
immunized by intramuscular injection (Figure 4A and 4B). IgG
and IgA levels were the lowest in that were vaccinated orally
regardless of whether they had pre-existing immunity (Figure 4A
and 4B). Immunization by the nasal route induced a strong IgG
response that was reduced by an average of 25% in the presence of
pre-existing immunity. The strongest IgA response was detected in
samples obtained from animals given the vaccine by the nasal
route. IgA levels, however, were also reduced by 25% in mice with
pre-existing immunity to Ad5.
Effect of Mucosal Immunization on Survival Against
Lethal Ebola Challenge in the Presence of Pre-Existing
Immunity
The most direct means of evaluating vaccine efficacy in mice is
to assess protection by monitoring weight loss and death rates after a
lethal challenge of Ebola [43]. Therefore, mice were immunized
with 1610
10 particles of Ad5-ZGP by the intramuscular (I.M.),
intranasal (I.N.) or oral (P.O.) route in the presence or absence of
Figure 1. Pre-Existing Immunity Against Adenovirus Does not
Compromise the Strength of the Cellular and Humoral Immune
Response Against Ebola Glycoprotein After Intranasal Immu-
nization. Naı ¨ve mice (n=10) were vaccinated with a single dose of
1610
10 particles of adenovirus expressing the Ebola Zaire glycoprotein
(Ad5-ZGP) by the intramuscular (I.M.), nasal (I.N.) or oral (P.O.) route.
Animals in which pre-existing immunity (PEI) was established by I.M.
injection of 5610
10 particles of adenovirus serotype 5 expressing beta-
galactosidase (AdlacZ) 30 days prior to vaccination were also
immunized in the same manner. At the time of vaccination, mice had
an average anti-adenovirus circulating NAB titer of 1:320. Animals given
a single dose of (AdlacZ) served as negative controls (AdlacZ Control).
(A) Frequency analysis of IFN-c secreting CD8+ T cells harvested from
splenocytes 10 days post-immunization (n=4/group). The TELRTFSI
peptide, specific for the Ebola Zaire glycoprotein (0.4 mg/well), was
incubated with 1610
6 splenocytes and cells analyzed by flow
cytometry. (B) Neutralizing antibody (NAB) levels against ZEBOV-EGFP
were evaluated 25 days post-vaccination (n=10/group). In both panels,
error bars represent the standard deviation of the data.
doi:10.1371/journal.pone.0003548.g001
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average anti-adenovirus neutralizing antibody titer of 1:320
reciprocal dilution. Naı ¨ve mice vaccinated by intramuscular
injection with saline (vehicle) served as controls for complete lethality
following challenge with mouse-adapted Ebola virus. Twenty-eight
days after vaccination, animals were challenged with 200 LD50 of
mouse-adapted (MA)-ZEBOV. Only mice immunized by the nasal
route survived the lethal challenge (Figure 5A). This was evident as
earlyas5daysafterchallengewhencontrolsandmiceimmunizedby
the other routes began to lose weight (Figure 5B). All eventually
expired 7 days post-challenge (Figure 5A, some data not shown for
clarity). In contrast, naı ¨ve mice given the vaccine survived challenge
regardless of the route of administration.
Effect of PEGylation on Improving the Immune Response
Achieved by Oral Vaccination
The studies outlined above strongly suggest that only intranasal
immunization can successfully afford protection against Ebola virus
in the absence and presence of pre-existing immunity. It was also
clear that additional strategies were needed to improve vaccination
by either the oral or intramuscular route in the presence of pre-
existing immunity. Covalent attachment of activated monomethox-
ypolyethylene glycol to the protein capsid of the Ad5-ZGP vector
was evaluated as a potential way to improve the immune response
after oral vaccination. Based upon previous observations, we
hypothesized that this modification would protect the virus from
neutralization by immune sera and improve survival in gastrointes-
tinal tract [26,27,30,44]. The frequency of Ebola glycoprotein
peptide-specific activation of IFN-c positive CD8+ T cells was not
significant in naı ¨ve animals given the PEGylated virus (0.360.3%)
with respect to those given the unmodified virus (2.060.5%,
p=0.09, Figure 6A). Similar results were also seen in the presence
of pre-existing immunity in either treatment group (0.460.2%
PEGylated vaccine, 1.760.5%, unmodified vaccine).
In contrast, NAB levels equivalent to 30610 reciprocal dilution
were detected in naı ¨ve animals given the PEGylated vaccine
(Figure 6B). Samples obtained from animals given the unmodified
virus had levels of 2065 reciprocal dilution. Animals with pre–
existing immunity against adenovirus and treated with the
PEGylated preparation were also able to produce detectable
Figure 2. Pre-Existing Immunity Against Adenovirus Does Not Compromise the Systemic or Mucosal Cellular Response Generated
Against Ebola Glycoprotein After Intranasal Immunization. The frequency of IFN-c positive mononuclear cells was analyzed from the spleen
(panels A and C), the lung via bronchioalveolar lavage (BAL) and the intestine via the mesenteric lymph nodes (MLN) and Peyer’s patches (PP) (panels
B and D) 45 days post-immunization by ELISPOT. Samples were obtained from naı ¨ve animals (Panels A and B) and those with pre-existing immunity
to adenovirus serotype 5 (Panels C and D). Cells were plated at 1610
5 or 1610
4 cells per well, stimulated with the TELRTFSI peptide and expression of
IFN-c detected with an anti-mouse IFN-c antibody. Cells isolated from BAL, MLN or PP of four mice were pooled and samples tested in duplicate. In
each panel, the number of spot-forming cells (SFC) per million mononuclear cells (MNCs) is shown on the y-axis. Please note - the scale of this axis
differs between panels to accent the differences between treatment groups. Error bars represent the standard deviation of the data. Animals
immunized with an irrelevant adenoviral vector (AdlacZ) served as negative controls. Positive results obtained from this group are indicative of
artificial cellular stimulation that may have occurred during processing and culturing of samples.
doi:10.1371/journal.pone.0003548.g002
Nasal Immunization for Ebola
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found in sera from mice given the unmodified vector orally.
Further characterization of Ebola glycoprotein-specific Ig isotypes
revealed that the PEGylated vector could possibly stimulate
production of IgG in the presence or absence of pre-existing
immunity with respect to levels found in animals given the
unmodified vector (Figure 6C). Modification of the virus induced a
slight increase of IgA in the presence of pre-existing immunity with
respect to that seen in naı ¨ve animals given unmodified virus
(Vaccine, Figure 6D) and those with pre-existing immunity
(Vaccine+PEI). Despite this, animals with pre-existing immunity
to adenovirus and immunized with the PEGylated vaccine orally
did not survive after challenge with 200 LD50 of (MA)-ZEBOV.
Discussion
Withmortalityratesashighas95%,Ebolainfectionoccurslargely
by direct contact with blood, tissues or skin of patients, and through
mucosal exposure [45,46]. To date, few efforts have been made to
focus on the mucosa as the primary sight of exposure to Ebola virus
and priming it for participation in the host defense by vaccination
[47]. This is surprising given that the pulmonary, nasal and oral
immune systems which comprise the mucosal-associated lymphoid
tissues (MALT) are responsible for the production of approximately
80% of all immunocytes [48,49] and mucosal immunity is often the
first line of defense against pathogens coming in contact with
susceptible hosts. Many studies in rodents indicate that systemic
immunization produces strong anti-viral systemic responses while
mucosal vaccination can stimulate both the mucosal and systemic
immune systems and can confer long-term immunological memory
against a given pathogen despite the fact that the magnitude of these
responsesareoftenreported tobesomewhatreduced[37,48,50].We
have found this to be the case in the studies outlined here since the
systemic cellular response and neutralizing antibody levels against
Ebola Zaire GP were consistently lower following nasal and oral
vaccination. Mucosal vaccination did, however, generate significant
cellular and antibody responses in the periphery (BAL, MLN or
Peyer’s patches) and a single intranasal immunization with Ad5-
ZGP conferred 100% protection even in the presence of pre-existing
immunity.
Administration of recombinant adenovirus-based vaccines to
the mucosa has also conferred sufficient protection against
challenge with a variety of pathogens in the presence of pre-
existing immunity to the vaccine carrier in mice and other pre-
clinical models of disease [5,19,32,51,52]. This served as a basis for
the present study. A single intranasal dose of a recombinant Ad5
vaccine expressing the Zaire Ebola glycoprotein conferred 100%
protection in both naı ¨ve mice and those with pre-existing
immunity despite the fact that the strength of the immune
response generated by this route of administration was quantita-
tively lower than that seen in animals vaccinated by intramuscular
injection. It is also important to note that pre-existing immunity
induced by intramuscular injection did not severely compromise
the T cell-mediated response at either the systemic or mucosal
levels in these animals. The level of anti-Ebola GP antibodies in
the circulation and in the lung was also not significantly
compromised by pre-existing immunity to adenovirus. While
these results suggest that intranasal vaccination with an Ad-based
vaccine is indeed a promising strategy to overcome pre-existing
immunity, one might wonder how accurately our results translate
Figure 3. Intranasal Immunization Induces Production of
Neutralizing Antibodies in the Lung in the Presence of Pre-
Existing Immunity. Forty-five days after immunization, bronchioalve-
loar fluid was analyzed for the presence of neutralizing antibody by
measuring the reduction in infectious titer of ZEBOV-EGFP. The
reciprocal dilution plotted for each treatment group (n=10) reflects
the dilution at which the ability of the ZEBOV-EGFP vector to infect
target cells was reduced by .50%. Data represent average values
obtained from each treatment group and error bars represent the
standard deviation of the data. NOTE - Data grouped on the left side of
the figure under the label ‘‘Serum’’ is reproduced from Figure 1B of this
manuscript and is included here for comparison. PEI - pre-existing
immunity to adenovirus serotype 5.
doi:10.1371/journal.pone.0003548.g003
Figure 4. Intranasal Vaccination Induces Anti-Ebola Specific Ig
Isotypes in Bronchioalveolar Lavage Fluid in the Absence and
Presence of Pre-Existing Immunity. Forty-five days after immuni-
zation, bronchioalveolar lavage fluid was analyzed for Ebola-specific IgG
(panel A) and IgA (panel B) antibodies by ELISA. The optical densities
obtained from each treatment group are presented to serve as a
measure of relative concentration. PEI - pre-existing immunity to
adenovirus serotype 5.
doi:10.1371/journal.pone.0003548.g004
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This is somewhat difficult to establish in the mouse model since the
ability of the wild-type adenovirus to replicate is limited [53]. In
addition, the amount of neutralizing antibody present in the nasal
cavity of those in the general population with pre-existing immunity
to adenovirus 5 has not been assessed to the degree that serum
neutralizing antibodies have, making it difficult to set a relative
parameter for one to target in pre-clinical animal models. Lack of
this data may be due to the invasive nature of the technique for
acquiring samples and/or the fact that antibody levels in the mucosa
of individuals with established pre-existing immunity to adenovirus
type 5 are quite low and transient in contrast to systemic levels of
anti-adenovirus neutralizing antibodies which are quite robust and
persist over time (unreported observations). Thus, for these studies,
we decided to induce pre-existing immunity against adenovirus by
intramuscular injection at a dose that has been shown to induce
production of systemic neutralizing antibodies at 1:320, a level
mostly below what was reported in humans with documented pre-
existingimmunity[8,11,12].Additionalstudiesdesigned toassessthe
amount of neutralizing antibody to AdHu5 in the lung over time
after intranasal administration of varying doses of AdHu5 are
currently underway in an effort to further define stringent conditions
under which pre-existing immunity can be established for experi-
mental testing.
Data obtained from animals vaccinated by the oral route provided
several insights about the immunological requirements for protection
against Ebolain a mouse model.Immunization by thisroute induced
quantitativelylowerTandBcellmediatedimmuneresponsesagainst
Ebola glycoprotein with respect to that achieved by either
intramuscular or intranasal immunization. Despite this, every naı ¨ve
animal immunized with a single oral dose of Ad-ZGP survived
challenge, giving better precision on the minimal threshold of
immunity required to achieve protection. As seen with intranasal
immunization, the T cell-mediated response was not compromised
by pre-existing immunity 10 days after oral vaccination. The number
of IFN-c secreting T cells in both mucosal and systemic
compartments of these animals at day 45, however, was significantly
reduced by pre-existing immunity. It is possible that the peak T cell
response at day 10 does not reflect the extent by which pre-existing
immunity decreases the Ad5-ZGP-induced T cell response. Alterna-
tively, it is also possible that the ELISPOT assay could detect subtle
variations that flow cytometery could not monitor accurately due to
differences in the sensitivity of each assay. Neutralizing antibody was
not detected in the serum of animals with pre-existing immunity
given a single oral dose of the vaccine. More importantly, none of
these animals survived challenge with mouse adapted Ebola.
We attempted to improve the immunogenicity of the adenovi-
rus-based vaccine by protecting it from the harsh environment of
the gastrointestinal tract and from neutralization by anti-
adenovirus antibodies by PEGylation. Interestingly, the T-cell
mediated immune response was significantly reduced and
antibody levels increased in naı ¨ve animals given a single oral dose
of the PEGylated vaccine with respect to that seen in animals given
the same dose of unmodified Ad5-ZGP. It has been shown that
modification of virus capsids by PEGylation can significantly
dampen the T-cell mediated immune response against the virus
and stimulate the antibody response against a secreted antigen
[26,27,30,54]. Taken together, these data support the notion that
the exposition of the virus capsid proteins facilitates the immune
response against the encoded antigen. Optimization of PEGylation
chemistries and/or densities on adenovirus-based vaccine that
promote and strengthen protective immune responses following
oral immunization is currently underway.
Delivery of recombinant adenoviral vaccines to either the nasal
or intestinal mucosa is an attractive vaccination strategy for many
reasons. Vaccines administered in this manner will offer improved
safety with respect to disease transmission and needle-stick injuries
among health care workers, significant issues of concern in
developing countries where the demand for many vaccines is high
[55]. Mucosal administration of vaccines reduces the pain
associated with vaccination, eliminates the need for specialized
training programs for large vaccination campaigns and makes self-
administration of the vaccine possible. This route of administra-
tion may also significantly reduce systemic toxicity associated with
recombinant adenovirus despite the fact that it has been shown
that nasal immunization with recombinant adenovirus-based
vaccines can facilitate translocation of the virus to the central
nervous system [52]. Even though testing of other virus-based
vaccines such as influenza have reported similar findings and are
currently used in the clinic [56], studies designed to fully assess the
Figure5.IntranasalImmunizationwithRecombinantAdenovirus
Expressing Ebola Glycoprotein Affords Protection Against
Lethal Challenge Even in the Presence of Pre-Existing Immunity.
Naı ¨ve mice (n=10) were vaccinated with a single dose of 1610
10 particles
of adenovirus expressing the Ebola glycoprotein (Ad5-ZGP) by the
intramuscular (I.M.), nasal (I.N.) or oral (P.O.) route. Animals in which pre-
existing immunity (PEI) was established by I.M. injection of 5610
10
particles ofadenovirus 5 expressingbeta-galactosidase (AdlacZ) were also
vaccinated in the same manner. Twenty-eight days later, mice were
challenged with 200 LD50 of mouse-adapted Ebola virus (Zaire strain).
Data represent survival (panel A) and loss of body weight (panel B) over
time and is reported as average body weight from each treatment group.
Mock - age matched, untreated, unchallenged mice included in this data
set to indicate normal weight variation over time. NOTE: Data for naı ¨ve
mice immunized by the oral route (P.O.) and those with pre-existing
immunity and vaccinated by the I.M. route (I.M.+PEI) were not included in
this figure for visual clarity. All naive mice immunized orally survived
challenge while none in the I.M.+PEI group survived.
doi:10.1371/journal.pone.0003548.g005
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tion are also currently underway.
We have shown that nasal immunization with an Ad5-based
vaccine can induce a long-term protective immune response
against Ebola virus in a mouse model which is not impeded by pre-
existing immunity to adenovirus serotype 5. While these results are
extremely encouraging, further characterization of the immune
response against both the encoded antigen and the adenovirus
vector in larger, clinically relevant animal models is vital for both
understanding the biology of Ad vaccines and for the development
of an effective Ebola vaccine suitable to populations with different
requirements [57,58]. The issue of pre-existing immunity must
also be adequately addressed in order to develop efficient
recombinant adenovirus-based vaccines. While the majority of
the literature suggests that pre-existing immunity significantly
hamper the effective use of AdHu5 vaccine carriers, other
investigators have reported that pre-existing immunity did not
interfere with the potency of recombinant Ad5-based vaccines in
both pre-clinical models of disease and in humans [59,60]. Thus,
additional studies identifying clinically relevant conditions under
which to test Ad-based vaccine candidates are necessary to assess
the full impact of pre-existing immunity on vaccine potency,
including in different compartments. Better define the role of pre-
existing immunity on vaccine-induced immunity will further the
understanding of how individuals previously exposed to adenovi-
rus will respond to these immunization regimens.
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